BIA UK BioScience Forum: The benefits of the European Unitary Patent

14 October 2013
london-big

Updates on Intellectual Property developments in Europe were heard by delegates at the BIA UK BioScience Forum last week, writes The Pharma Letter’s Sophie Flowers.

Rebecca Baines, senior associate of patent legal experts Rouse, gave an update on the European Unitary Patent which will come into force in two years’ time. This will affect all applications for new patents in the European Union. She said that despite the potential benefits of the unitary patent, such as it being cheaper and more accessible for companies, there are still mixed feelings about it.

The current situation

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical